248 related articles for article (PubMed ID: 34954439)
1. Immunotherapy in older patients with hepatocellular carcinoma.
Lyu N; Yi JZ; Zhao M
Eur J Cancer; 2022 Feb; 162():76-98. PubMed ID: 34954439
[TBL] [Abstract][Full Text] [Related]
2. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.
Zhu Y; Qin LX
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):420-429. PubMed ID: 35977874
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
4. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
5. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model.
Sové RJ; Verma BK; Wang H; Ho WJ; Yarchoan M; Popel AS
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323435
[TBL] [Abstract][Full Text] [Related]
6. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Wong KM; King GG; Harris WP
Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
[TBL] [Abstract][Full Text] [Related]
7. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
Celsa C; Cabibbo G; Fulgenzi CAM; Scheiner B; D'Alessio A; Manfredi GF; Nishida N; Ang C; Marron TU; Saeed A; Wietharn B; Pinter M; Cheon J; Huang YH; Lee PC; Phen S; Gampa A; Pillai A; Vivaldi C; Salani F; Masi G; Roehlen N; Thimme R; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; El Tomb P; Ulahannan S; Parisi A; Chon HJ; Hsu WF; Stefanini B; Verzoni E; Giusti R; Veccia A; Catino A; Aprile G; Guglielmini PF; Di Napoli M; Ermacora P; Antonuzzo L; Rossi E; Verderame F; Zustovich F; Ficorella C; Di Pietro FR; Battelli N; Negrini G; Grossi F; Bordonaro R; Pipitone S; Banzi M; Ricciardi S; Laera L; Russo A; De Giorgi U; Cavanna L; Sorarù M; Montesarchio V; Bordi P; Brunetti L; Pinto C; Bersanelli M; Cammà C; Cortellini A; Pinato DJ
J Hepatol; 2024 Mar; 80(3):431-442. PubMed ID: 37972660
[TBL] [Abstract][Full Text] [Related]
9. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
[TBL] [Abstract][Full Text] [Related]
10. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
11. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
[TBL] [Abstract][Full Text] [Related]
14. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
[TBL] [Abstract][Full Text] [Related]
15. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy.
Li SQ; Yang Y; Ye LS
World J Gastroenterol; 2022 Nov; 28(42):6034-6044. PubMed ID: 36405383
[TBL] [Abstract][Full Text] [Related]
18. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
Liu L; Qin S; Zhang Y
Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
[TBL] [Abstract][Full Text] [Related]
19. The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials.
Cammarota A; Zanuso V; D'Alessio A; Pressiani T; Bozzarelli S; Personeni N; Rimassa L
Expert Opin Investig Drugs; 2022 Apr; 31(4):425-435. PubMed ID: 35152830
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
Jiang J; Huang H; Chen R; Lin Y; Ling Q
Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
